vs
LIGAND PHARMACEUTICALS INC（LGND）与REPUBLIC BANCORP INC（RBCAA）财务数据对比。点击上方公司名可切换其他公司
REPUBLIC BANCORP INC的季度营收约是LIGAND PHARMACEUTICALS INC的1.6倍（$94.3M vs $59.7M），LIGAND PHARMACEUTICALS INC净利率更高（75.1% vs 24.2%，领先50.8%），LIGAND PHARMACEUTICALS INC同比增速更快（39.4% vs 5.3%），REPUBLIC BANCORP INC自由现金流更多（$161.1M vs $45.9M），过去两年LIGAND PHARMACEUTICALS INC的营收复合增速更高（38.8% vs -11.5%）
利根制药是美国的生物制药企业，专注于收购和开发可产生特许权使用费的资产。截至2024年，公司的资产组合涵盖约90款覆盖多个治疗领域的药品的特许权使用权，可从多发性骨髓瘤治疗药物凯洛斯、Evomela，肾病治疗药物Filspari，以及肺炎球菌疫苗Vaxneuvance等知名产品中获得相关收益。
肯塔基州共和银行是美国的一家区域性银行控股企业，提供零售及商业银行全品类服务，涵盖个人存贷款、企业融资、按揭产品及财富管理解决方案，主要服务肯塔基州及周边州的个人消费者和中小企业客户。
LGND vs RBCAA — 直观对比
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $59.7M | $94.3M |
| 净利润 | $44.8M | $22.8M |
| 毛利率 | — | — |
| 营业利润率 | 23.2% | 29.3% |
| 净利率 | 75.1% | 24.2% |
| 营收同比 | 39.4% | 5.3% |
| 净利润同比 | 244.1% | 20.0% |
| 每股收益（稀释后） | $2.42 | — |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
| Q4 25 | $59.7M | $94.3M | ||
| Q3 25 | $115.5M | $93.5M | ||
| Q2 25 | $47.6M | $93.8M | ||
| Q1 25 | $45.3M | $135.8M | ||
| Q4 24 | $42.8M | $89.5M | ||
| Q3 24 | $51.8M | $88.1M | ||
| Q2 24 | $41.5M | $86.9M | ||
| Q1 24 | $31.0M | $120.3M |
| Q4 25 | $44.8M | $22.8M | ||
| Q3 25 | $117.3M | $29.7M | ||
| Q2 25 | $4.8M | $31.5M | ||
| Q1 25 | $-42.5M | $47.3M | ||
| Q4 24 | $-31.1M | $19.0M | ||
| Q3 24 | $-7.2M | $26.5M | ||
| Q2 24 | $-51.9M | $25.2M | ||
| Q1 24 | $86.1M | $30.6M |
| Q4 25 | 23.2% | 29.3% | ||
| Q3 25 | 47.6% | 40.4% | ||
| Q2 25 | 17.7% | 43.0% | ||
| Q1 25 | -79.9% | 44.1% | ||
| Q4 24 | -22.5% | 25.8% | ||
| Q3 24 | 6.1% | 38.4% | ||
| Q2 24 | -46.0% | 37.0% | ||
| Q1 24 | 9.6% | 32.2% |
| Q4 25 | 75.1% | 24.2% | ||
| Q3 25 | 101.6% | 31.8% | ||
| Q2 25 | 10.2% | 33.5% | ||
| Q1 25 | -93.6% | 34.8% | ||
| Q4 24 | -72.6% | 21.2% | ||
| Q3 24 | -13.8% | 30.1% | ||
| Q2 24 | -125.0% | 29.0% | ||
| Q1 24 | 278.1% | 25.4% |
| Q4 25 | $2.42 | — | ||
| Q3 25 | $5.68 | — | ||
| Q2 25 | $0.24 | — | ||
| Q1 25 | $-2.21 | — | ||
| Q4 24 | $-1.70 | — | ||
| Q3 24 | $-0.39 | — | ||
| Q2 24 | $-2.88 | — | ||
| Q1 24 | $4.75 | — |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $733.5M | $220.0M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $1.0B | $1.1B |
| 总资产 | $1.6B | $7.0B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
| Q4 25 | $733.5M | $220.0M | ||
| Q3 25 | $664.5M | $484.2M | ||
| Q2 25 | $245.0M | $484.8M | ||
| Q1 25 | $208.9M | $793.0M | ||
| Q4 24 | $256.2M | $432.2M | ||
| Q3 24 | $219.6M | $530.9M | ||
| Q2 24 | $226.9M | $400.1M | ||
| Q1 24 | $310.6M | $546.4M |
| Q4 25 | $1.0B | $1.1B | ||
| Q3 25 | $950.2M | $1.1B | ||
| Q2 25 | $828.5M | $1.1B | ||
| Q1 25 | $795.5M | $1.0B | ||
| Q4 24 | $830.4M | $992.0M | ||
| Q3 24 | $841.2M | $979.7M | ||
| Q2 24 | $775.2M | $955.4M | ||
| Q1 24 | $806.5M | $935.6M |
| Q4 25 | $1.6B | $7.0B | ||
| Q3 25 | $1.5B | $7.0B | ||
| Q2 25 | $948.6M | $7.0B | ||
| Q1 25 | $905.4M | $7.1B | ||
| Q4 24 | $941.8M | $6.8B | ||
| Q3 24 | $954.9M | $6.7B | ||
| Q2 24 | $866.4M | $6.6B | ||
| Q1 24 | $913.9M | $6.9B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $45.9M | $168.2M |
| 自由现金流经营现金流 - 资本支出 | $45.9M | $161.1M |
| 自由现金流率自由现金流/营收 | 76.9% | 170.9% |
| 资本支出强度资本支出/营收 | 0.0% | 7.5% |
| 现金转化率经营现金流/净利润 | 1.03× | 7.37× |
| 过去12个月自由现金流最近4个季度 | $48.9M | $288.6M |
8季度趋势，按日历期对齐
| Q4 25 | $45.9M | $168.2M | ||
| Q3 25 | $13.1M | $33.3M | ||
| Q2 25 | $15.8M | $8.4M | ||
| Q1 25 | $-25.4M | $93.2M | ||
| Q4 24 | $28.5M | $149.0M | ||
| Q3 24 | $36.5M | $51.3M | ||
| Q2 24 | $13.3M | $4.0M | ||
| Q1 24 | $18.7M | $71.2M |
| Q4 25 | $45.9M | $161.1M | ||
| Q3 25 | $13.1M | $30.8M | ||
| Q2 25 | $15.6M | $5.2M | ||
| Q1 25 | $-25.7M | $91.6M | ||
| Q4 24 | $27.8M | $143.2M | ||
| Q3 24 | $35.9M | $49.8M | ||
| Q2 24 | $12.9M | $2.7M | ||
| Q1 24 | $18.6M | $69.1M |
| Q4 25 | 76.9% | 170.9% | ||
| Q3 25 | 11.3% | 32.9% | ||
| Q2 25 | 32.7% | 5.5% | ||
| Q1 25 | -56.6% | 67.4% | ||
| Q4 24 | 64.8% | 160.0% | ||
| Q3 24 | 69.4% | 56.5% | ||
| Q2 24 | 31.1% | 3.1% | ||
| Q1 24 | 60.1% | 57.5% |
| Q4 25 | 0.0% | 7.5% | ||
| Q3 25 | 0.0% | 2.6% | ||
| Q2 25 | 0.4% | 3.5% | ||
| Q1 25 | 0.5% | 1.2% | ||
| Q4 24 | 1.7% | 6.5% | ||
| Q3 24 | 1.2% | 1.7% | ||
| Q2 24 | 1.0% | 1.5% | ||
| Q1 24 | 0.3% | 1.7% |
| Q4 25 | 1.03× | 7.37× | ||
| Q3 25 | 0.11× | 1.12× | ||
| Q2 25 | 3.26× | 0.27× | ||
| Q1 25 | — | 1.97× | ||
| Q4 24 | — | 7.84× | ||
| Q3 24 | — | 1.93× | ||
| Q2 24 | — | 0.16× | ||
| Q1 24 | 0.22× | 2.33× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
LGND
| Intangible Royalty Assets | $40.7M | 68% |
| Financial Royalty Assets | $9.8M | 16% |
| Material Sales Captisol | $7.8M | 13% |
| Vaxneuvance | $1.4M | 2% |
RBCAA
暂无分部数据
